Vitamin 15 (HEMO15) Injection, compounded by Olympia Pharmacy, Orlando, FL
Published July 17, 2013 · Recall initiated: May 29, 2013
Summary
FDA records drug Class II recall D-789-2013, published July 17, 2013 and initiated May 29, 2013. Recalling firm: Lowlite Investments, Inc. D/B/A Olympia Pharmacy; Status: Ongoing; Reported quantity: 1; Lot: A5011 Exp 7/10/13. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Lowlite Investments, Inc. D/B/A Olympia Pharmacy
- Distributor
- Nationwide and PR
- Lot
- A5011 Exp 7/10/13
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAKetamine 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDAMetabolase Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDAAcetyl-D-Glucosamine w/Chondroitin 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDADiclazuril 10 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDATripelennamine 20 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
- FDAVitamin A/D3/E Olive Oil Injection, compounded by Olympia Pharmacy, Orlando, FLJuly 17, 2013
Questions about this recall
Was Vitamin 15 (HEMO15) Injection, compounded by Olympia Pharmacy, Orlando, FL recalled?
Yes. FDA published recall D-789-2013 on July 17, 2013. Reported hazard: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit